The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback